The United States market has demonstrated robust performance, climbing 1.4% in the last week and achieving a 26% increase over the past year, with earnings projected to grow by 19% annually. In this thriving environment, growth companies with strong insider ownership can be particularly appealing as they often align management interests with those of shareholders, potentially enhancing long-term value creation.

Top 10 Growth Companies With High Insider Ownership In The United States

Name	Insider Ownership	Earnings Growth
Uxin (UXIN)	34.3%	79.5%
Upstart Holdings (UPST)	14.1%	58.5%
On Holding (ONON)	26%	23.2%
Laird Superfood (LSF)	17%	109.9%
Karman Holdings (KRMN)	15.6%	52.6%
Figure Technology Solutions (FIGR)	25.9%	54.1%
Corcept Therapeutics (CORT)	10.9%	48.9%
Circle Internet Group (CRCL)	11.8%	49%
Astera Labs (ALAB)	10%	29.3%
AppLovin (APP)	27.2%	21.7%

We'll examine a selection from our screener results.

Abeona Therapeutics (ABEO)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing gene and cell therapies for life-threatening diseases in the United States, with a market cap of $328.86 million.

Operations: Abeona Therapeutics Inc. currently does not report any revenue segments, as indicated by the absence of revenue data in their financial disclosures.

Insider Ownership: 16.5%

Earnings Growth Forecast: 32.9% p.a.

Abeona Therapeutics is trading significantly below its fair value, with revenue expected to grow at 40.5% annually, outpacing both industry and market averages. Despite a net loss of US$17.08 million in Q1 2026, earnings are forecast to rise by 32.9% per year. Recent board changes include the resignation of Michael Amoroso and the appointment of Keith A. Goldan, indicating strategic leadership adjustments amid substantial insider buying over the past three months.

Niagen Bioscience (NAGE)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Niagen Bioscience, Inc. is a bioscience company focused on developing healthy aging products and has a market cap of $279.34 million.

Operations: The company generates revenue primarily from Consumer Products ($98.58 million), Ingredients ($29.07 million), and Analytical Reference Standards and Services ($2.69 million).

Insider Ownership: 24.8%

Earnings Growth Forecast: 23% p.a.

Niagen Bioscience's revenue is forecast to grow at 15.6% annually, surpassing the US market's average. The company reported Q1 2026 sales of US$31.47 million and net income of US$6.32 million, showing year-over-year growth. Despite trading below its estimated fair value, Niagen is expanding its product offerings with the launch of a telehealth platform and strategic partnerships for its Niagen Plus line, enhancing access to pharmaceutical-grade products and supporting future growth prospects.

York Space Systems (YSS)

Simply Wall St Growth Rating: ★★★★★☆

Overview: York Space Systems, Inc. is a space and defense company offering mission-critical solutions for national security, government, and commercial clients in the U.S., with a market cap of $3.99 billion.

Operations: The company generates revenue of $396.29 million from its Aerospace & Defense segment, serving national security, government, and commercial sectors in the U.S.

Insider Ownership: 10.2%

Earnings Growth Forecast: 104.9% p.a.

York Space Systems is experiencing rapid growth with forecasted revenue expansion of 27.2% annually, outpacing the US market. The company has secured significant contracts, including a recent U.S. government award for national security missions, enhancing its defense capabilities and expanding its customer base. Despite a volatile share price and current unprofitability, York is trading below estimated fair value and continues to invest in scalable manufacturing and next-generation space architectures to support future growth.

Taking Advantage

• Embark on your investment journey to our 169 Fast Growing US Companies With High Insider Ownership selection here.
• Looking For Alternative Opportunities? Uncover 26 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.